Abstract:Introduction: Pulmonary fibrosis includes a spectrum of diseases and is incurable. There is a variation in disease course, but it is often progressive leading to increased breathlessness, impaired quality of life, and decreased life expectancy. Detection of pulmonary fibrosis is challenging, which contributes to considerable delays in diagnosis and treatment. More knowledge about the diagnostic journey from patients' perspective is needed to improve the diagnostic pathway. The aims of this study were to evaluate the time to diagnosis of pulmonary fibrosis, identify potential reasons for delays, and document patients emotions. Methods: Members of European patient organisations, with a self-reported diagnosis of pulmonary fibrosis, were invited to participate in an online survey. The survey assessed the diagnostic pathway retrospectively, focusing on four stages: (1) time from initial symptoms to first appointment in primary care; (2) time to hospital referral; (3) time to first hospital appointment; (4) time to final diagnosis. It comprised open-ended and closed questions focusing on time to diagnosis, factors contributing to delays, diagnostic tests, patient emotions, and information provision. Results: Two hundred and seventy three participants (214 idiopathic pulmonary fibrosis, 28 sarcoidosis, 31 other) from 13 countries responded. Forty percent of individuals took ≥1 year to receive a final diagnosis. Greatest delays were reported in stage 1, with only 50.2% making an appointment within 3 months. For stage 2, 73.3% reported a hospital referral within three primary care visits. However, 9.9% reported six or more visits. After referral, 76.9% of patients were assessed by a specialist within 3 months (stage 3) and 62.6% received a final diagnosis within 3 months of their first hospital visit (stage 4). Emotions during the journey were overall negative. A major need for more information and support during and after the diagnostic process was identified. Conclusion: The time to diagnose pulmonary fibrosis varies widely across Europe. Delays occur at each stage of the diagnostic pathway. Raising awareness about pulmonary fibrosis amongst the general population and healthcare workers is essential to shorten the time to diagnosis. Furthermore, there remains a need to provide patients with sufficient information and support at all stages of their diagnostic journey.

Assessment of the impact of social deprivation, distance to hospital and time to diagnosis on survival in idiopathic pulmonary fibrosis

Investigating the Impact of Social Determinants of Health on Diagnostic Delays and Access to Antifibrotic Treatment in Idiopathic Pulmonary Fibrosis

Spectrum of disease and predictors of mortality in patients with idiopathic pulmonary fibrosis in South Africa

Changes in survival in people with IPF in England 2010-2020

Idiopathic Pulmonary Fibrosis in the United Kingdom: Findings from the first decade of the largest single-country IPF Registry

A study on the prevalence and prognosis of progressive pulmonary fibrosis: A retrospective observational study

Small airway dysfunction in idiopathic pulmonary fibrosis

Risk factors for diagnostic delay in idiopathic pulmonary fibrosis

Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in England from 2008 to 2018: a cohort study

Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis-related interstitial lung disease

Retrospective Study on Prognostic Factors of Idiopathic Pulmonary Fibrosis

Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions

The Impact of Chronic Comorbidities on Outcomes in Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Referral to pulmonary rehabilitation and palliative care services in people with idiopathic pulmonary fibrosis in England, 2010–2019

Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study

Proportion and predictors of FVC decline in patients with interstitial lung disease

PM2.5 and NO2 exposure are associated with worse prognosis in IPF: Analysis of the UK PROFILE study

Comparison of disease progression subgroups in idiopathic pulmonary fibrosis

Prognosis and Follow-Up of Idiopathic Pulmonary Fibrosis

Patient Reported Experiences and Delays During the Diagnostic Pathway for Pulmonary Fibrosis: A Multinational European Survey

Relevance Analysis of Clinical and Lung Function Parameters Changing and Prognosis of Idiopathic Pulmonary Fibrosis.